8-K current report · filed Aug 11, 2026

Bicara Therapeutics Inc. (BCAX) 8-K Current Report: August 11, 2026

Item EX-99.1Item 2.02BCAX overview

Short answer

Bicara Therapeutics Inc. (BCAX) filed an 8-K current report with the SEC on August 11, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results and business updates announced for quarter ended June 30, 2026.

Bicara Therapeutics Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results and business updates announced for quarter ended June 30, 2026
  • Full results and operational details available in Exhibit 99.1 press release
  • Investor focus: quarterly performance, cash position and clinical-development updates in the attached release

Item EX-99.1 · Exhibit EX-99.1

  • Leadership succession: Ryan Cohlhepp becomes CEO January 1, 2027, while Claire Mazumdar transitions to Vice Chair and Strategic Advisor
  • FORTIFI-HN01 pivotal trial expected substantially enrolled by year-end, targeting interim topline results in mid-2027
  • Cash, equivalents and marketable securities $497.3M, supporting operations into the first half of 2029 under current plans
  • Second-quarter net loss $55.4M, versus $27.4M in 2025, reflecting sharply higher clinical and commercialization investment
  • FORTIFI-FLEX initiated to test 1,500mg weekly loading followed by 2,250mg every three weeks with pembrolizumab

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Bicara Therapeutics Inc. 8-K filings

Get the next BCAX 8-K as it lands

Follow BCAX for push alerts, or ask the research agent what this filing means.